For nearly six decades, flow cytometry (FC) has been a cornerstone in clinical and laboratory research, with applications spanning immune-phenotyping, diagnostics, cell counting, and cell cycle analysis. Its strength lies in its ability to measure multiple parameters simultaneously by assessing cell properties through light scatter and fluorescence. Cells suspended in saline solution pass through a laser light source via hydrodynamic focusing, enabling the measurement of cell diameter via forward scatter (FSC) and granularity via side scatter (SSC). Fluorescent dyes and antibodies enhance cell characterization, and FC can also perform fluorescence-activated cell sorting (FACS) for separating cells into distinct populations.
In recent years, traditional FC faced limitations such as restricted parameter numbers due to detector constraints, high detection thresholds, and subjective result interpretation. These challenges spurred innovations like spectral flow cytometry, nanoparticle flow cytometry, and droplet cytometry, which aim to enhance accuracy and efficiency.
Spectral flow cytometry captures the full emission spectra of fluorophores across multiple detectors, allowing differentiation between fluorochromes with overlapping peaks. This technology removes physical color limitations, enabling automated, reliable analysis. It has proven valuable in cancer research for analyzing immune signatures and tumor infiltrates, with potential to measure up to 100 parameters, revolutionizing biomarker prediction and personalized medicine.
Nanoparticle flow cytometry addresses sensitivity limitations, detecting tiny extracellular vesicles (EVs) and their cargo at low concentrations. Optimized assays and calibration allow comprehensive analysis of EVs, which are crucial in physiological functions and hold clinical promise. This advancement supports standardized reporting frameworks like MIFlowCyt-EV, enhancing reproducibility and clinical translation.
Double droplet cytometry uses double emulsion droplets to protect cellular components, enabling high-throughput analysis of proteins and enzymatic activity. It allows observation of phenomena such as cell-secreted proteins and cell-cell interactions, advancing synthetic biology by efficiently screening protein libraries.
Looking ahead, quantum cytometry may enable single-molecule detection, transitioning FC into a fully quantitative technology with unprecedented sensitivity. Combined with ongoing advancements, FC is poised for greater sensitivity, efficiency, and accessibility, driven by shared facilities and trained operators.
In summary, flow cytometry’s future is bright, with innovations addressing past limitations and opening new research and clinical avenues. Continued collaboration, training, and standardization will be crucial in unlocking its full potential.
